Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

No evidence that analgesic use after COVID-19 vaccination negatively impacts antibody responses

View ORCID ProfileBonnie J. Lafleur, Lisa White, Michael D. Dake, View ORCID ProfileJanko Nikolich-Zugich, Ryan Sprissler, View ORCID ProfileDeepta Bhattacharya
doi: https://doi.org/10.1101/2022.10.14.22281103
Bonnie J. Lafleur
1BIO5 Institute, University of Arizona, Tucson, AZ, USA
2Department of Pharmacy Practice and Science, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bonnie J. Lafleur
Lisa White
1BIO5 Institute, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Dake
3Office of the Senior Vice-President for Health Sciences, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janko Nikolich-Zugich
1BIO5 Institute, University of Arizona, Tucson, AZ, USA
4Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ, USA
5University of Arizona Center on Aging, University of Arizona College of Medicine, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Janko Nikolich-Zugich
Ryan Sprissler
1BIO5 Institute, University of Arizona, Tucson, AZ, USA
6University of Arizona Genomics Core and the Arizona Research Labs, University of Arizona Genetics Core, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepta Bhattacharya
1BIO5 Institute, University of Arizona, Tucson, AZ, USA
4Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ, USA
7Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Deepta Bhattacharya
  • For correspondence: deeptab@arizona.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Vaccines against SARS-CoV-2, the virus that causes COVID-19, showed high efficacy against symptomatic illness caused by the ancestral strain. Yet recent variants such as Omicron and its sublineages substantially escape vaccine-induced neutralizing antibodies. In response, bivalent mRNA booster vaccines updated to better match the BA.4-5 lineages have been made available. Yet the reactogenicity of these vaccines might negatively impact willingness to receive the booster immunization. While serious side effects following vaccination are rare, mRNA vaccines frequently lead to mild adverse events such as injection site pain, lymphadenopathy, myalgia, and fever. Over-the-counter analgesics might mitigate some of these mild adverse events, but animal models of SARS-CoV-2 infection have shown that non-steroidal anti-inflammatory drugs (NSAIDs) substantially reduce antiviral antibody responses, which are the best correlates of protection against COVID-19. It remains unknown whether these same inhibitory effects are seen in humans after mRNA vaccination. We surveyed 6,010 individuals who received COVID-19 vaccines regarding analgesic use and correlated these results with Spike-specific antibody levels. We found no negative impact of analgesic use on antibody levels, and in fact observed slightly elevated concentrations of anti-Spike antibodies in individuals who used painkillers. Logistic regression analyses demonstrated a higher proportion of those experiencing fatigue and muscle aches between NSAID users and those not taking pain medication, suggesting that the elevated antibody levels were likely associated with inflammation and mild adverse events rather than analgesic use per se. Together, our results suggest no detriment to painkiller use to alleviate symptoms after vaccination against COVID-19.

Competing Interest Statement

Sana Biotechnology has licensed intellectual property of D.B. and Washington University in St. Louis. Gilead Sciences has licensed intellectual property of D.B. and Stanford University. Clade Therapeutics has licensed intellectual property of D.B. and The University of Arizona. D.B. is a co-founder of Clade Therapeutics. D.B. served on an advisory panel for GlaxoSmithKline on COVID-19 therapeutics. D.B., R.S., J.N.Z., and The University of Arizona hold a patent on SARS-CoV-2 serological assays.

Funding Statement

Supported in part by NIH R01AI129945 and NIH R01AI099108 (D.B.) and and the Bowman Professorship in Medical Sciences (J.N.-Z).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study, collection, and use of human blood was approved by the University of Arizona Institutional Review Board (Protocol#2102460536).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 17, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
No evidence that analgesic use after COVID-19 vaccination negatively impacts antibody responses
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
No evidence that analgesic use after COVID-19 vaccination negatively impacts antibody responses
Bonnie J. Lafleur, Lisa White, Michael D. Dake, Janko Nikolich-Zugich, Ryan Sprissler, Deepta Bhattacharya
medRxiv 2022.10.14.22281103; doi: https://doi.org/10.1101/2022.10.14.22281103
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
No evidence that analgesic use after COVID-19 vaccination negatively impacts antibody responses
Bonnie J. Lafleur, Lisa White, Michael D. Dake, Janko Nikolich-Zugich, Ryan Sprissler, Deepta Bhattacharya
medRxiv 2022.10.14.22281103; doi: https://doi.org/10.1101/2022.10.14.22281103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1254)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10043)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2477)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1650)
  • Health Policy (756)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11886)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2298)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1255)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (736)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2291)
  • Public and Global Health (4849)
  • Radiology and Imaging (844)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)